Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-C3 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARO-C3 (Healthy Volunteers) | EXPERIMENTAL | 1 or 2 doses of ARO-C3 by subcutaneous (sc) injection |
| Placebo (Healthy Volunteers) | PLACEBO_COMPARATOR | placebo calculated volume to match active treatment by sc injection |
| ARO-C3 (Adult Patients with C3G or IgAN) | EXPERIMENTAL | 3 doses of ARO-C3 by sc injection |
| Name | Type | Description |
|---|---|---|
| ARO-C3 | DRUG | ARO-C3 for sc injection |
| Placebo | DRUG | sterile normal saline (0.9% NaCl) for sc injection |
Inclusion Criteria (All Participants): * Willing to provide written informed consent and to comply with study requirements * Female participants must be non-pregnant/non-lactating * Healthy volunteers must be willing to be vaccinated with a meningococcal and pneumococcal vaccine. C3G and IgAN parti...
ARO-C3 is an investigational small molecule being developed for C3 Glomerulopathy, a rare kidney disease. It is also being studied in IgA Nephropathy, another complement-mediated renal condition. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ARO-C3 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker ARWR. The company is conducting clinical trials to evaluate the safety and efficacy of ARO-C3 in patients with complement-mediated renal diseases.
ARO-C3 is in Phase 1 clinical development. A Phase 1 study has been completed, involving 62 participants, including healthy volunteers and patients with complement-mediated renal disease. The drug is investigational and has not yet received FDA approval.
ARO-C3 has been studied in a Phase 1 clinical trial with the identifier NCT05083364. This trial, titled 'Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease,' was completed and enrolled 62 participants across multiple countries including Australia, Georgia, Germany, New Zealand, South Korea, Thailand, and the United Kingdom.
ARO-C3 is the primary name for this investigational drug. No alternative names have been reported for ARO-C3. It is a distinct asset being developed by Arrowhead Pharmaceuticals for the treatment of complement-mediated renal diseases.